Hagège J, Delarue F, Peraldi M N, Sraer J D, Rondeau E
Inserm U 64 and Association Claude Bernard, Hôpital Tenon, Paris, France.
Lab Invest. 1994 Dec;71(6):828-37.
Mesangial changes in a variety of pathologic conditions involve mesangial cell proliferation and mesangial matrix remodelling. Heparin has been shown to prevent these processes in vivo. In vitro, heparin interferes with cell growth, proto-oncogene expression, synthesis of specific proteins, and extracellular matrix composition. In some cell types, it seems to interact with intracellular protein kinase C-dependent pathways. The effect of heparin on the mesangial plasminogen activating system (tissue type plasminogen activator, t-PA, and plasminogen activator inhibitor type 1, PAI-1), which is thought to be involved in matrix remodelling, has not been previously reported.
Cultured human mesangial cells were stimulated by 10% fetal calf serum (FCS) or 16 nM phorbol myristate acetate (PMA) in the presence or absence of anticoagulant or nonanticoagulant heparins. Cell proliferation, synthesis of t-PA and PAI-1, cell morphology, and PAI-1 matrix deposition were studied using cell counting, [3H]thymidine incorporation, specific t-PA and PAI-1 enzyme-linked immunosorbent assay, Northern blot analysis, light microscopy, immunofluorescence and immunogold silver staining with combined bright-field and epipolarization microscopy.
Heparin partially inhibited FCS-stimulated cell growth but not PMA-induced thymidine incorporation. FCS and PMA stimulated t-PA (p < 0.05 and p < 0.01, respectively) and PAI-1 synthesis (p < 0.05 and p < 0.01 respectively). Heparin selectively and partially inhibited FCS-stimulated t-PA, but not PAI-1 synthesis. It has no effect on PMA-stimulated t-PA or PAI-1 synthesis but prevented cell shape-changes induced by PMA, suggesting that heparin inhibits some but not all protein kinase C (PKC)-dependent effects and that heparin block in t-PA synthesis is distal to PKC activation. Heparin decreased PAI-1 matrix accumulation. Similar distal to PKC activation. Heparin decreased PAI-1 matrix accumulation. Similar results were observed with anticoagulant and nonanticoagulant heparin fragments.
In human mesangial cells, anticoagulant and nonanticoagulant heparin exert an antiproliferative effect and may prevent mesangial matrix changes by decreasing FCS-stimulated t-PA synthesis and PAI-1 deposition in the matrix. Heparin is able to inhibit PKC-dependent cell shape changes but not PKC-dependent t-PA or PAI-1 synthesis. It also inhibits PKC-independent cell proliferation and t-PA synthesis. These results suggest multiple intracellular sites of action for heparin, unrelated or distal to PKC activation.
多种病理状况下的系膜变化涉及系膜细胞增殖和系膜基质重塑。肝素已被证实在体内可预防这些过程。在体外,肝素可干扰细胞生长、原癌基因表达、特定蛋白质合成及细胞外基质组成。在某些细胞类型中,它似乎与细胞内蛋白激酶C依赖性途径相互作用。肝素对被认为参与基质重塑的系膜纤溶酶原激活系统(组织型纤溶酶原激活物,t-PA,和纤溶酶原激活物抑制剂1型,PAI-1)的影响此前尚未见报道。
在有或无抗凝或非抗凝肝素存在的情况下,用10%胎牛血清(FCS)或16 nM佛波酯(PMA)刺激培养的人系膜细胞。使用细胞计数、[3H]胸腺嘧啶核苷掺入、特异性t-PA和PAI-1酶联免疫吸附测定、Northern印迹分析、光学显微镜、免疫荧光以及结合明场和落射偏光显微镜的免疫金银染色研究细胞增殖、t-PA和PAI-1合成、细胞形态以及PAI-1基质沉积。
肝素部分抑制FCS刺激的细胞生长,但不抑制PMA诱导的胸腺嘧啶核苷掺入。FCS和PMA刺激t-PA(分别为p < 0.05和p < 0.01)和PAI-1合成(分别为p < 0.05和p < 0.01)。肝素选择性地部分抑制FCS刺激的t-PA,但不抑制PAI-1合成。它对PMA刺激的t-PA或PAI-1合成无影响,但可防止PMA诱导的细胞形态改变,这表明肝素抑制部分而非全部蛋白激酶C(PKC)依赖性效应,且肝素对t-PA合成的阻断位于PKC激活的下游。肝素减少PAI-1基质积聚。类似地在PKC激活的下游。肝素减少PAI-1基质积聚。抗凝和非抗凝肝素片段也观察到类似结果。
在人系膜细胞中,抗凝和非抗凝肝素发挥抗增殖作用,并可能通过减少FCS刺激的t-PA合成和PAI-1在基质中的沉积来预防系膜基质变化。肝素能够抑制PKC依赖性细胞形态改变,但不能抑制PKC依赖性t-PA或PAI-1合成。它还抑制不依赖PKC的细胞增殖和t-PA合成。这些结果提示肝素存在多个细胞内作用位点,与PKC激活无关或位于其下游。